Humanwell Healthcare (600079.SH) has obtained the registration certificate for niacin sustained-release tablets.

Humanwell Healthcare (600079.SH) announced that its holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., recently received the "Drug Registration Certificate" for the approved release of nicotinic acid sustained-release tablets from the National Medical Products Administration. Nicotinic acid sustained-release tablets are used for adult patients with primary hypercholesterolemia and mixed dyslipidemia, to lower levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (ApoB), and triglycerides (TG), while also increasing levels of high-density lipoprotein cholesterol (HDL-C).